Romeg Therapeutics Announces Publication of RMG-03 Phase 2 Study Results in COVID-19

WOBURN, Mass., April 4, 2023 /PRNewswire/ — ROMEG Therapeutics, LLC (“Romeg”), an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced the publication of results from its recently completed Phase 2 proof of concept study of RMG-03 in COVID-19 patients. The results from the ...

Read More

Romeg Therapeutics Announces Issuance of U.S. Patent for Pilocarpine Oral Solution

WOBURN, Mass., Feb. 1, 2023 /PRNewswire/ — ROMEG Therapeutics, LLC (“Romeg”), an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,564,909 (the ‘909 patent) directed to the methods and composition ...

Read More

Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.

Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is large and projected to be $8.3 billion ...

Read More